VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CERS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CERSCerus Corporation
$3.22$645M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

CERS logoCerus Corporation(CERS)Earnings, Financials & Key Ratios

CERS•NASDAQ
$3.22
Price updated Jul 7, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryRenal, dialysis, and blood purification
AboutCerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.Show more
  • Revenue$206M+14.3%
  • EBITDA-$34M-177.7%
  • Net Income-$16M+25.3%
  • EPS (Diluted)-0.08+25.5%
  • Gross Margin53.5%-3.1%
  • EBITDA Margin-16.66%-142.8%
  • Operating Margin-17.63%-123.5%
  • Net Margin-7.58%+34.7%
  • ROE-25.65%+32.4%

CERS Price & Volume

Cerus Corporation (CERS) stock price & volume — 10-year historical chart

Loading chart...

Pathogen Reduction Growth Faces Persistent Liquidity Constraints

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Expanding
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and dilution risk

Key Thesis Takeaways

  • Cerus Corporation demonstrates promising top-line momentum with 24.1% year-over-year revenue growth in 2026Q1, yet the company remains fundamentally challenged by an inability to achieve consistent operating leverage.
  • While the INTERCEPT system continues to gain market traction, the persistent reliance on high R&D spending—often exceeding $15 million per quarter—and significant stock-based compensation masks a precarious cash burn profile.
  • Investors should remain cautious as the company's $27.9 million cash position and negative retained earnings of $1.1 billion suggest a high probability of future dilutive financing to sustain operations.

Verdict Logic

the company's thin liquidity buffer of $27.9 million in cash against persistent operational losses and a P/FCF multiple of 68.65 suggests that the current valuation does not adequately account for the risk of near-term shareholder dilution.

CERS Growth Metrics

Cerus Corporation (CERS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years19.67%
5 Years17.53%
3 Years8.35%
TTM16.97%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM49.6%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM49.61%

Return on Capital

10 Years-42.06%
5 Years-24.31%
3 Years-21.59%
Last Year-28.14%

CERS Recent Earnings

Cerus Corporation (CERS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
Apr 30, 2026
Metric
Actual
Est
EPS
$0.01+66.7%
$0.03
Rev
$60M+7.6%
$56M
Q2 2026
Mar 2, 2026
Metric
Actual
Est
EPS
$0.01+0.0%
$0.01
Rev
$65M+4.5%
$62M
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$0.00+99.5%
$0.02
Rev
$53M-11.1%
$59M
Q3 2025
Aug 5, 2025
Metric
Actual
Est
EPS
$0.03-50.0%
$0.02
Rev
$52M-3.4%
$54M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 30, 2026
$0.01vs $0.03+66.7%
$60Mvs $56M+7.6%
Q2 2026Mar 2, 2026
$0.01vs $0.01+0.0%
$65Mvs $62M+4.5%
Q4 2025Nov 6, 2025
$0.00vs $0.02+99.5%
$53Mvs $59M-11.1%
Q3 2025Aug 5, 2025
$0.03vs $0.02-50.0%
$52Mvs $54M-3.4%
Based on last 12 quarters of dataView full earnings history →

Latest CERS News

Recent stock market news and headlines for Cerus Corporation (CERS)

Business Wire·Jun 17, 2026
Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT Congress. “We look forward to highlighting how blood centers around the world are l.

Peers Comparison

Key metrics vs top competitors for Cerus Corporation (CERS)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CERS logoCERSCerus CorporationCurrent
$3.22$645.19M-39.2714.35%-7.58%-25.65%—
TXG logoTXG10x Genomics, Inc.
$37.83$4.8B-108.095.25%-3.55%-2.86%—
BLFS logoBLFSBioLife Solutions, Inc.
$27.93$1.36B-111.7216.97%-10.52%-2.91%—
NTRA logoNTRANatera, Inc.
$281.27$40.28B-185.0535.9%-9.05%-15.13%—
AGEN logoAGENAgenus Inc.
$3.50$145.75M-1029.4110.37%52.16%——
HAE logoHAEHaemonetics Corporation
$74.88$3.48B36.53-1.97%7.29%11.32%—

Compare CERS vs Peers

Cerus Corporation (CERS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs TXG

Most directly comparable listed peer for CERS.

Scale Benchmark

vs ABT

Larger-name benchmark to compare CERS against a more recognizable public peer.

Peer Set

Compare Top 5

vs TXG, BLFS, NTRA, AGEN

CERS SEC Filings & Documents

Cerus Corporation (CERS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 30, 2026·SEC

Material company update

Apr 21, 2026·SEC

Material company update

Mar 16, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 2, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Mar 5, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 30, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 5, 2025·SEC

Get notified when CERS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CERS Frequently Asked Questions

Cerus Corporation (CERS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Cerus Corporation's revenue?

Cerus Corporation (CERS) reported $216.6M in revenue for fiscal year 2025. This represents a 3038% increase from $6.9M in 1997.

How fast is Cerus Corporation growing?

Cerus Corporation (CERS) grew revenue by 14.3% over the past year. This is steady growth.

Is CERS profitable?

Cerus Corporation (CERS) reported a net loss of $9.6M for fiscal year 2025.

Dividend & Returns
What is CERS's return on equity?

Cerus Corporation (CERS) has a return on equity (ROE) of -25.6%. Negative ROE indicates the company is unprofitable.

What is Cerus Corporation's free cash flow?

Cerus Corporation (CERS) had negative free cash flow of $1.2M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in CERS back in 1997?

Total return calculator · dividends reinvested · 29+ years of data

See returns →